Roswell Park Experts Highlight Untapped Potential of CDK Inhibitor Cancer Therapy - Summary - MDSpire
From the Journals

Roswell Park Experts Highlight Untapped Potential of CDK Inhibitor Cancer Therapy

Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of cancer cells.

  • May 11, 2026

  • 3 min

Share

Approximately one million breast cancer patients worldwide have benefitted from CDK4/6 inhibitors that inhibit cancer cell multiplication. Researchers aim to extend these therapies to other cancer types by overcoming treatment resistance. Published developments in Nature Reviews Drug Discovery reveal the evolution of CDK inhibitors, emphasizing the need for novel drug combinations, biomarker identification, and more selective inhibitors to enhance patient outcomes and personalize treatment, especially in advanced cancers, as highlighted by experts from Roswell Park Comprehensive Cancer Center.

Original Source(s)

Roswell Park Experts Highlight Untapped Potential of CDK Inhibitor Cancer Therapy

  • May 11, 2026

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Roswell Park Study: Inhibiting Regulator Protein Can Make Aggressive Prostate Cancers More Vulnerable

Team shows BCL-2 promotes treatment resistance, uncovering strategy for making tumors respond to treatment.

  • by

  • May 11, 2026

  • 4 min
New Research Sheds Light on How Precancerous Lesions Form in the Pancreas

Discoveries about two metabolic enzymes could point the way to biomarkers, opportunities to prevent cancer.

  • by

  • May 11, 2026

  • 3 min